May 15, 2012
Announces Second Quarter Results for Fiscal 2012
Announces Second Quarter Results for Fiscal 2012
May 4, 2012
Announces CAD$10,000,800 Bought Deal Common Share Financing
Announces CAD$10,000,800 Bought Deal Common Share Financing
April 16, 2012
Announces Change of Auditors
Announces Change of Auditors
March 19, 2012
Announces Approval of $8.3 Million Debt Facility
Announces Approval of $8.3 Million Debt Facility
March 15, 2012
Announces First Quarter Results for Fiscal 2012
Announces First Quarter Results for Fiscal 2012
VANCOCIN® capsules
Clostridium difficile infection (CDI) causes watery or mucousy diarrhea, lower abdominal pain and systemic symptoms such as fever, anorexia, nausea and malaise when mildly symptomatic, and life-threatening toxic megacolon when severe.
While metronidazole has been the first-line therapy against CDI, recent clinical studies have shown that vancomycin is clinically superior to metronidazole for the treatment of severe CDI. Treatment with vancomycin resulted in 97% cure rate vs. 76% in metronidazole-treated group... [more]
Symbol: MSLI
Last:
Change:
Date:
Time:
Last:
Change:
Date:
Time:
Symbol: MSL
Last:
Change:
Date:
Time:
Last:
Change:
Date:
Time:
Quotes are delayed at least 15 minutes.
Copyright © 2012 Merus Labs Inc. All Rights Reserved.